Back to Report Store Home

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

  • Published: Mar-2017
  • Report Code: GBIHC433MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumonia Incidence, 2015–2022 17

Figure 2: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Pneumococcal Vaccinations (million), 2015–2022 18

Figure 3: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for PAH, 2015–2022 19

Figure 4: Respiratory Complications Therapeutics Market, Global, Epidemiology Patterns for Tuberculosis, 2015–2022 19

Figure 5: Respiratory Complications Therapeutics Market, Global, Prevnar 13 Revenue Forecast, 2015–2022 31

Figure 6: Respiratory Complications Therapeutics Market, Global, Synflorix Revenue Forecast, 2015–2022 32

Figure 7: Respiratory Complications Therapeutics Market, Global, Uptravi Revenue Forecast, 2016–2022 33

Figure 8: Respiratory Complications Therapeutics Market, Global, Opsumit Revenue Forecast, 2015–2022 34

Figure 9: Respiratory Complications Therapeutics Market, Global, Eliquis Revenue Forecast, 2015–2022 35

Figure 10: Respiratory Complications Therapeutics Market, Global, Xarelto Revenue Forecast, 2015–2022 37

Figure 11: Respiratory Complications Therapeutics Market, Global, Synagis Revenue Forecast, 2015–2022 38

Figure 12: Respiratory Complications Therapeutics Market, Global, Ventolin Revenue Forecast, 2015–2022 39

Figure 13: Respiratory Complications Therapeutics Market, Global, Infanrix Revenue Forecast, 2015–2022 40

Figure 14: Respiratory Complications Therapeutics Market, Global, Boostrix Revenue Forecast, 2015–2022 41

Figure 15: Respiratory Complications Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 43

Figure 16: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2017 44

Figure 17: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2017 45

Figure 18: Respiratory Complications Therapeutics Market, Global, Pipeline by Molecular Target, 2017 47

Figure 19: Respiratory Complications Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2017 48

Figure 20: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017 49

Figure 21: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017 50

Figure 22: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017 51

Figure 23: Respiratory Complications Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017 52

Figure 24: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 53

Figure 25: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 54

Figure 26: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 55

Figure 27: Respiratory Complications Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 56

Figure 28: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017 56

Figure 29: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017 57

Figure 30: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017 58

Figure 31: Respiratory Complications Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017 59

Figure 32: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2017 60

Figure 33: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006???2017 60

Figure 34: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017 61

Figure 35: Respiratory Complications Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2017 62

Figure 36: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Solithera ($m), 2017–2022 64

Figure 37: Respiratory Complications Therapeutics Market, Global, Revenue Forecast for Carbavance ($m), 2017–2022 65

Figure 38: Respiratory Complications Therapeutics Market, Global, Revenue for Respiratory Syncytial Virus Vaccine ($m), 2018–2022 66

Figure 39: Respiratory Complications Therapeutics Market, Global, Market Size ($bn), 2015–2022 68

Figure 40: Respiratory Complications Therapeutics Market, Global, Annual Revenue by Generic Products ($m), 2015–2022 70

Figure 41: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Vaccines ($bn), 2015–2022 71

Figure 42: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting G-Protein Coupled Receptors ($bn), 2015–2022 71

Figure 43: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Enzymes ($bn), 2015–2022 72

Figure 44: Respiratory Complications Therapeutics Market, Global, Annual Revenue Forecast for Drugs with Bacterial/Viral Targets ($bn), 2015–2022 73

Figure 45: Respiratory Complications Therapeutics Market, Global, Company Analysis Matrix, 2015–2022 74

Figure 46: Respiratory Complications Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 76

Figure 47: Respiratory Complications Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), Base Year–2022 77

Figure 48: Respiratory Complications Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015–2022 78

Figure 49: Respiratory Complications Therapeutics Market, Global, Actelion Annual Revenue ($bn), 2015–2022 79

Figure 50: Respiratory Complications Therapeutics Market, Global, GSK Annual Revenue ($bn), 2015–2022 80

Figure 51: Respiratory Complications Therapeutics Market, Global, Bayer Annual Revenue ($bn), 2015–2022 81

Figure 52: Respiratory Complications Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenue ($bn), 2015–2022 82

Figure 53: Respiratory Complications Therapeutics Market, Global, Novavax Annual Revenue ($m), 2018–2022 83

Figure 54: Respiratory Complications Therapeutics Market, Global, United Therapeutics Annual Revenue ($bn), 2015–2022 84

Figure 55: Respiratory Complications Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 85

Figure 56: Respiratory Complications Therapeutics Market, Global, Companies by Type, 2017 86

Figure 57: Respiratory Complications Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Specialization, 2017 87

Figure 58: Respiratory Complications Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Complications, 2015–2022 88

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards